Hookipa Pharma’s (HOOK) Buy Rating Reaffirmed at HC Wainwright

Hookipa Pharma (NASDAQ:HOOKGet Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $6.50 price target on the stock. HC Wainwright also issued estimates for Hookipa Pharma’s FY2028 earnings at $0.31 EPS.

Separately, Royal Bank of Canada decreased their price objective on shares of Hookipa Pharma from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Tuesday, January 30th.

Check Out Our Latest Stock Report on HOOK

Hookipa Pharma Price Performance

Shares of NASDAQ HOOK opened at $0.72 on Monday. The company has a market cap of $60.36 million, a P/E ratio of -0.82 and a beta of 1.03. Hookipa Pharma has a 1 year low of $0.41 and a 1 year high of $2.05. The firm has a 50-day simple moving average of $0.70 and a two-hundred day simple moving average of $0.63.

Hedge Funds Weigh In On Hookipa Pharma

Institutional investors have recently modified their holdings of the stock. CHI Advisors LLC purchased a new position in shares of Hookipa Pharma during the second quarter worth approximately $694,000. XTX Topco Ltd purchased a new position in shares of Hookipa Pharma during the second quarter worth approximately $298,000. Goldman Sachs Group Inc. increased its position in shares of Hookipa Pharma by 117.8% during the first quarter. Goldman Sachs Group Inc. now owns 87,217 shares of the company’s stock worth $199,000 after acquiring an additional 47,168 shares during the period. Renaissance Technologies LLC increased its holdings in Hookipa Pharma by 50.2% during the third quarter. Renaissance Technologies LLC now owns 142,200 shares of the company’s stock valued at $191,000 after buying an additional 47,500 shares during the period. Finally, State Street Corp increased its holdings in Hookipa Pharma by 18.5% during the second quarter. State Street Corp now owns 169,174 shares of the company’s stock valued at $149,000 after buying an additional 26,367 shares during the period. 83.02% of the stock is owned by hedge funds and other institutional investors.

Hookipa Pharma Company Profile

(Get Free Report)

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Further Reading

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.